Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Driving the next generation of endocrinology care. See our social community guidelines: https://crinetics.com/social-media-community-guidelines/

We are a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine disease and endocrine-related tumors. Driven by the belief that no one should be defined by their disease, we’re transforming endocrine care to significantly improve the lives of patients, caregivers, and loved ones. As the premier, endocrine-rooted pharmaceutical company, we’re shaping the future of treatment, empowering individuals to live beyond their condition, and thrive. Learn more at www.crinetics.com.

Crinetics announces the randomization of the first patient in a Phase 3 trial of an investigational treatment being stud...
11/20/2025

Crinetics announces the randomization of the first patient in a Phase 3 trial of an investigational treatment being studied in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. Read more: https://bit.ly/3X6kKcn

11/11/2025

This Veterans Day, we proudly recognize our very own Bill Branch, who served 26 years in the U.S. Marine Corps Reserve, leading with trust, teamwork, and purpose. Today, he brings that same dedication and leadership to his role as Director of Federal & State Government Accounts at Crinetics.

We salute Bill and all those who’ve served for their strength, sacrifice, and commitment to something greater than themselves.

This World NETs Cancer Day, we reaffirm our commitment to people living with neuroendocrine tumors (NETs). We were proud...
11/10/2025

This World NETs Cancer Day, we reaffirm our commitment to people living with neuroendocrine tumors (NETs). We were proud to meet with clinical leaders and patient advocacy partners in the NETs space at the recent NANETs meeting to explore how we can continue advancing science for those impacted by NETs. Learn more about how we’re driving innovating in this space: https://bit.ly/3XbsFVK

11/01/2025

Many people have never heard of acromegaly, and even fewer understand what it’s really like to live with it. We asked people living with acromegaly what they wish others knew about the condition. Here’s what they shared ⬇️

We’re excited to be attending the 2025 North American Neuroendocrine Tumor Society Annual Meeting. Read more about our i...
10/23/2025

We’re excited to be attending the 2025 North American Neuroendocrine Tumor Society Annual Meeting. Read more about our involvement: https://bit.ly/3JmXUtP

10/08/2025

Say hello to Guapo! 🐾 Living up to his name, Guapo is Torrie Plata’s handsome pup who loves bringing joy, cuddles, and a little extra sunshine to the office. We’re proud to be a workplace where dogs are part of our pack, wagging tails included: https://bit.ly/3BmigiR

10/02/2025

Earlier this week, we celebrated our Nasdaq Opening Bell ceremony, a milestone fueled by patients, science, and the Crinetics team. Here’s to advancing the future of endocrine medicine together.

People living with acromegaly often face challenges that extend beyond their treatments. Chief Commercial Officer Isabel...
10/02/2025

People living with acromegaly often face challenges that extend beyond their treatments. Chief Commercial Officer Isabel Kalofonos shares Crinetics’ perspective on addressing barriers to care, supporting timely diagnosis, and raising awareness about the impact of this severe chronic condition. Read more: https://bit.ly/42JcCSz

09/25/2025

Today is an important day for the acromegaly community: the U.S. FDA has approved the first once-daily, oral treatment for adults with acromegaly.

We’re proud to have the opportunity to bring a new option to this community.

🔗 Press release: https://bit.ly/4pGArEi

09/24/2025

Congratulations to our very own Greg Solis for completing the world-renowned 2025 Ultra-Trail du Mont Blanc! His grit and passion reflect the spirit of curiosity and perseverance that powers our team and our science.

This past weekend, members of the Crinetics team had the privilege of attending the CARES Foundation, Inc Patient Educat...
09/23/2025

This past weekend, members of the Crinetics team had the privilege of attending the CARES Foundation, Inc Patient Education Conference, where we connected with individuals living with congenital adrenal hyperplasia (CAH) and their families. We’re grateful to the CARES Foundation and the CAH community for creating a space filled with education, support, and shared purpose.

Address

6055 Lusk Boulevard
San Diego, CA
92121

Telephone

+18584506464

Website

Alerts

Be the first to know and let us send you an email when Crinetics Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Crinetics Pharmaceuticals:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category